Resomelagon is under clinical development by SynAct Pharma and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

Avadomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase II for Diffuse Large B-Cell Lymphoma.

Retifanlimab is under clinical development by Incyte and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma.

Tenalisib is under clinical development by Rhizen Pharmaceuticals and currently in Phase II for Marginal Zone B-cell Lymphoma.

Belrestotug is under clinical development by iTeos Therapeutics and currently in Phase II for Squamous Non-Small Cell Lung Cancer.

Tinostamustine is under clinical development by Mundipharma EDO and currently in Phase I for Diffuse Large B-Cell Lymphoma.

KH-903 is under clinical development by Chengdu Kanghong Pharmaceuticals Group and currently in Phase II for Metastatic Colorectal Cancer.

Lisocabtagene maraleucel is under clinical development by Bristol-Myers Squibb and currently in Phase II for Unspecified B-Cell Lymphomas.

CWP-291 is under clinical development by JW Pharmaceutical and currently in Phase II for Relapsed Acute Myeloid Leukemia.

Eltanexor is under clinical development by Karyopharm Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia.

Q-901 is under clinical development by Qurient and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase II drugs for Small-Cell Lung Cancer have a 26% phase transition ...

Sumecigrel is under clinical development by Jiangsu Vcare PharmaTech and currently in Pre-Registration for Ischemic Stroke.